Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 2
2004 3
2007 1
2008 2
2009 1
2010 4
2012 2
2013 2
2014 1
2015 4
2016 1
2017 2
2018 2
2019 1
2020 2
2021 5
2022 3
2023 3
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

35 results

Results by year

Filters applied: . Clear all
Page 1
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP, Jäger U, Jaglowski S, Andreadis C, Westin JR, Fleury I, Bachanova V, Foley SR, Ho PJ, Mielke S, Magenau JM, Holte H, Pantano S, Pacaud LB, Awasthi R, Chu J, Anak Ö, Salles G, Maziarz RT; JULIET Investigators. Schuster SJ, et al. N Engl J Med. 2019 Jan 3;380(1):45-56. doi: 10.1056/NEJMoa1804980. Epub 2018 Dec 1. N Engl J Med. 2019. PMID: 30501490 Clinical Trial.
Rituximab and plasmapheresis for severe post-transplant auto-immune hepatitis.
Dumortier J, Chouik Y, Hequet O, Hervieu V, Boillot O. Dumortier J, et al. Among authors: hequet o. Clin Res Hepatol Gastroenterol. 2022 Mar;46(3):101844. doi: 10.1016/j.clinre.2021.101844. Epub 2021 Dec 15. Clin Res Hepatol Gastroenterol. 2022. PMID: 34920142 No abstract available.
[How to perform leukapheresis for procurement of the staring material used for commercial CAR T-cell manufacturing: A consensus from experts convened by the SFGM-TC].
Carnoy S, Beaumont JL, Kanouni T, Parquet N, Beauvais D, Hequet O, Kanold J, Ballot C, Mialou V, Reppel L, Damaj G, Yakoub-Agha I, Chabannon C. Carnoy S, et al. Among authors: hequet o. Bull Cancer. 2021 Mar;108(3):295-303. doi: 10.1016/j.bulcan.2020.11.014. Epub 2021 Feb 17. Bull Cancer. 2021. PMID: 33610284 Review. French.
Inflammatory profile of convalescent plasma to treat COVID: Impact of amotosalen/UVA pathogen reduction technology.
Cognasse F, Hamzeh-Cognasse H, Duchez AC, Shurko N, Eyraud MA, Arthaud CA, Prier A, Heestermans M, Hequet O, Bonneaudeau B, Rochette-Eribon S, Teyssier F, Barlet-Excoffier V, Chavarin P, Legrand D, Richard P, Morel P, Mooney N, Tiberghien P. Cognasse F, et al. Among authors: hequet o. Front Immunol. 2022 Oct 7;13:1034379. doi: 10.3389/fimmu.2022.1034379. eCollection 2022. Front Immunol. 2022. PMID: 36275757 Free PMC article.
Effects of Genotypes and Treatment on Oxygenscan Parameters in Sickle Cell Disease.
Boisson C, Rab MAE, Nader E, Renoux C, Kanne C, Bos J, van Oirschot BA, Joly P, Fort R, Gauthier A, Stauffer E, Poutrel S, Kebaili K, Cannas G, Garnier N, Renard C, Hequet O, Hot A, Bertrand Y, van Wijk R, Sheehan VA, van Beers EJ, Connes P. Boisson C, et al. Among authors: hequet o. Cells. 2021 Apr 5;10(4):811. doi: 10.3390/cells10040811. Cells. 2021. PMID: 33916502 Free PMC article.
Inflammatory markers and auto-Abs to type I IFNs in COVID-19 convalescent plasma cohort study.
Cognasse F, Hamzeh-Cognasse H, Rosa M, Corseaux D, Bonneaudeau B, Pierre C, Huet J, Arthaud CA, Eyraud MA, Prier A, Duchez AC, Ebermeyer T, Heestermans M, Audoux-Caire E, Philippot Q, Le Voyer T, Hequet O, Fillet AM, Chavarin P, Legrand D, Richard P, Pirenne F, Gallian P, Casanova JL, Susen S, Morel P, Lacombe K, Bastard P, Tiberghien P. Cognasse F, et al. Among authors: hequet o. EBioMedicine. 2023 Jan;87:104414. doi: 10.1016/j.ebiom.2022.104414. Epub 2022 Dec 17. EBioMedicine. 2023. PMID: 36535107 Free PMC article.
35 results